HC Wainwright & Co. Reiterates Buy on Aadi Bioscience, Maintains $45 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Aadi Bioscience (NASDAQ:AADI) and maintained a $45 price target.
June 08, 2023 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aadi Bioscience receives a reiterated Buy rating from HC Wainwright & Co. analyst Robert Burns, with a maintained $45 price target.
The reiterated Buy rating and maintained $45 price target by HC Wainwright & Co. analyst Robert Burns indicates a positive outlook for Aadi Bioscience. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100